Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIa Study of Safety and Efficacy of Alpharadin® With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer

NCT01106352 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT01106352
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01106352 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIa Study of Safety and Efficacy of Alpharadin® With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer
Lead sponsor
Bayer
Phase
Phase 1/2
Overall status
Completed
Start date
July 31, 2010
Completion date
June 30, 2015
Enrollment
70 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

bone metastases, castration-resistant prostate cancer